Some images has been designed using resources from Unsplash & Pixabay & Pexels & Freepik and some icons from Flaticon
跳到主要內容
站內檢索
:::
▍研究成果
:::

2022

  1. JH Wang*, LW Wang, SY Liang, J Rosenberg, TJ Wang, SF Wu, CY Liu. Relationship between prescribed opioids, pain management satisfaction, and pain intensity in oncology outpatients. Support Care Cancer. 2022 Jan 3. (IF: 3.603; Health Care Sciences & Services 34/107; Oncology 147/242; Rehabilitation 9/68)
  2. KN Koh*, RX Wong, DE Lee, JW Han, HK Byun, HI Yoon, DS Kim, CJ Lyu, HJ Kang, KT Hong, JH Lee, IH Kim, JH Phi, SK Kim, TT Wong, HL Lee, IC Lai, YM Kang, YS Ra, SD Ahn, HJ Im, WS Looi, SYY Low, EEK Tan, HJ Park, SH Shin, H Fuji, CO Suh, YW Chen, JY Kim. Outcomes of intracranial germinoma-a retrospective multinational Asian study on effect of clinical presentation and differential treatment strategies. Neuro Oncol. 2021 Dec 22:noab295. (IF: 12.300; Clinical Neurology 7/208; Oncology 19/242)
  3. CH Lin*, TY Lai, YJ Chen, SK Lin. Social distance towards schizophrenia in health professionals. Asia Pac Psychiatry. 2021 Dec 16:e12506. (IF: 2.538; Psychiatry 85/144; Psychiatry 108/156)
  4. YL Liu*, HCY Su, CJ Feng, PJ Lien, CC Huang, YS Lin, YL Wang, TC Chao, CY Liu, JH Chiu, YF Tsai, LM Tseng. Clinical Impacts of Molecular Subtyping by Multigene Assay on Hormone Receptor Positive Breast Cancers. J Chin Med Assoc. 2021 Dec 21. (IF: 2.743; Medicine, General & Internal 62/169)
  5. HH Chen*, TW Ke, CW Huang, JK Jiang, CC Chen, YY Hsieh, HW Teng, BW Lin, YH Liang, Y SuL, HC Hsu, FC Kuan, YH Chou, J Lin, BR Lin, YY Chang, JY Wang. Taiwan Society of Colon and Rectal Surgeons Consensus on mCRC Treatment. Front Oncol. 2021 Nov 15;11:764912. (IF: 6.244; Oncology 62/242)
  6. HY Yu*, CP Li, YH Huang, SJ Hsu, YP Wang, YC Hsieh, WL Fang, KH Huang, AF Li, RC Lee, KL Lee, YH Wu, IC Lai, WC Yang, YP Hung, YC Wang, SH Chen, MH Chen, Y Chao. Microsatellite Instability, Epstein-Barr Virus, and Programmed Cell Death Ligand 1 as Predictive Markers for Immunotherapy in Gastric Cancer. Cancers (Basel). 2022 Jan 3;14(1):218. (IF: 6.639; Oncology 51/242)
  7. SC Chen*, YH Huang, MH Chen, YP Hung, RC Lee, YY Shao, Y Chao. Anti-PD-1 combined sorafenib versus anti-PD-1 alone in the treatment of advanced hepatocellular cell carcinoma: a propensity score-matching study. BMC Cancer. 2022 Jan 11;22(1):55. (IF: 4.430; Oncology 110/242)
  8. HW Wu*, SC Lin, CL Wu, Lee KL, CH Wu, ST Chen, HH Chen, YY Lee, YW Chen, CC Wu, TR Hsu, FC Chang. Indolent enhancing spinal lesions mimicking spinal metastasis in pediatric patients with malignant primary brain tumors. Sci Rep. 2022 Feb 2;12(1):1728. (IF: 4.380; Multidisciplinary Sciences 17/72)
  9. LJ Huang*, SJ Chen, YW Hu, CY Liu, PF Wu, SM Sun, SY Lee, YY Chen, CY Lee, YJ Chan, YC Chou, FD Wang. The impact of antimicrobial stewardship program designed to shorten antibiotics use on the incidence of resistant bacterial infections and mortality. Sci Rep. 2022 Jan 18;12(1):913. (IF: 4.380; Multidisciplinary Sciences 17/72)
  10. CL Chiang*, PC Tsai, YC Yeh, YH Wu, HS Hsu, YM Chen. Recent Advances in the Diagnosis and Management of Multiple Primary Lung Cancer. Cancers (Basel). 2022 Jan 4;14(1):242. (IF: 6.639; Oncology 51/242)
  11. HQ Mai*, QY Chen, D Chen, C Hu, K Yang, J Wen, J Li, YR Shi, F Jin, R Xu, J Pan, S Qu, P Li, C Hu, YC Liu, Y Jiang, X He, HM Wang, WT Lim, W Liao, X He, X Chen, Z Liu, X Yuan, Q Li, X Lin, S Jing, Y Chen, Y Lu, CY Hsieh, MH Yang, CJ Yen, J Samol, H Feng, S Yao, P Keegan, RH Xu. Publisher Correction: Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial. Nat Med. 2022 Jan;28(1):214. (IF: 53.440; Biochemistry & Molecular Biology 1/259; Cell Biology 2/195; Medicine, Research & Experimental 1/140)
  12. PH Lin*, SC Chen, LM Tseng, KJ Chang, AC Huang, KC Cheng, K Yang, HC Wu, TY Chao, YC Chang, PC Lin, WH Kuo, WL Kuo, CH Lin, HM Chen, DC Yeh, LC Liu, CY Liu, MY Wang, C Lo, YS Lu, CS Huang. Impact of BRCA mutation on the survival and risk of contralateral breast cancer in Asian breast cancer patients. Breast Cancer Res Treat. 2022 Feb 3. (IF: 4.872; Oncology 95/242)
  13. YC Chang*, PM Chang, CH Li, MH Chan, YJ Lee, MH Chen, M Hsiao. Aldolase A and Phospholipase D1 Synergistically Resist Alkylating Agents and Radiation in Lung Cancer. Front Oncol. 2022 Jan 21;11:811635. (IF: 6.244; Oncology 62/242)
  14. YM Kang*, YY Lee, SC Lin, FC Chang, HSP SuC, CF Lin, ML Liang, HH Chen, TT Wong, KL Lan, Y Chao, YW Chen. PLoS One. Bifocal lesions have a poorer treatment outcome than a single lesion in adult patients with intracranial germinoma. 2022 Mar 1;17(3):e0264641. (IF: 3.240; Multidisciplinary Sciences 26/72; Biology n/a)
  15. FT Hsu*, CL Tsai, IT Chiang, KH Lan, PF Yueh, WY Liang, CS Lin, Y Chao, KL Lan. Synergistic effect of Abraxane that combines human IL15 fused with an albumin-binding domain on murine models of pancreatic ductal adenocarcinoma. J Cell Mol Med. 2022 Feb 17. (IF: 5.310; Cell Biology 73/195; Medicine, Research & Experimental 44/140; Biochemistry & Molecular Biology n/a; Biophysics n/a)
  16. YP Yang*, AC Lee, LT Lin, YW Chen, PI Huang, HI Ma, YC Chen, WL Lo, YT Lan, WL Fang, CY Wang, YY Liu, PK Hsu, WC Lin, CP Li, MT Chen, CS Chien, ML Wang. Strategic Decoy Peptides Interfere with MSI1/AGO2 Interaction to Elicit Tumor Suppression Effects. Cancers (Basel). 2022 Jan 20;14(3):505. (IF: 6.639; Oncology 51/242)
  17. YY Pan*, LC Meng, HM Chen, LK Chen, FY Hsiao. Impact of Frailty on Survivals of Prostate Cancer Patients Treated with Radiotherapy. Arch Gerontol Geriatr. 2022 Feb 5;100:104651. (IF: 3.250; Geriatrics & Gerontology 34/53)
  18. SP Su*, SL Lin, YH Chan, YJ Lee, YC Lee, PX Zeng, YX Li, MH Yang, HK Chiang. Development of Stereo NIR-II Fluorescence Imaging System for 3D Tumor Vasculature in Small Animals. Biosensors (Basel). 2022 Jan 30;12(2):85. (IF: 5.519; Chemistry, Analytical 15/87; Instruments & Instrumentation 8/64; Nanoscience & Nanotechnology 42/106)
  19. KC Lai*, ZX Hong, JG Hsieh, HJ Lee, MH Yang, CH Hsieh, CH Yang, YR Chen. IFIT2-depleted metastatic oral squamous cell carcinoma cells induce muscle atrophy and cancer cachexia in mice. J Cachexia Sarcopenia Muscle. 2022 Feb 15. (IF: 12.910; Geriatrics & Gerontology 1/53; Medicine, General & Internal 9/167)
  20. CC Huang*, YF Tsai, CY Liu, PJ Lien, YS Lin, TC Chao, CJ Feng, YJ Chen, JI Lai, NN Phan, HCY Su, JH Chiu, LM Tseng. Prevalence of Tumor Genomic Alterations in Homologous Recombination Repair Genes Among Taiwanese Breast Cancers. Ann Surg Oncol. 2022 Feb 28. (IF: 5.334; Oncology 82/242; Surgery 19/211)
  21. WL Hwang*, TC Chen, HY Lin, MC Chang, PC Hsiao, LY Bai, CY Kuo, YC Chen, TC Liu, JP Gau, PN Wang, WS Hwang, MC Kuo, CY Liu, YC Liu, MC Ma, NW Su, CC Wang, YY Wu, M Yao, SP Yeh, HW Cheng, YM Lee, FC Ku, JL Tang. NOVEL-1st: an observational study to assess the safety and efficacy of nilotinib in newly diagnosed patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase in Taiwan. Int J Hematol. 2022 Feb 25. (IF: 2.490; Hematology 56/76)
  22. LJ Li*, PM Chang, CH Li, YC Chang, TC Lai, CY Su, CL Chen, WM Chang, M Hsiao, SW Feng. FAS receptor regulates NOTCH activity through ERK-JAG1 axis activation and controls oral cancer stemness ability and pulmonary metastasis. Cell Death Discov. 2022 Mar 5;8(1):101. (IF: 5.241; Cell Biology 76/195)
  23. YS Chang*, CW Su, SC Chen, YY Chen, YJ Liang, JC Wu. Upregulation of USP22 and ABCC1 during Sorafenib Treatment of Hepatocellular Carcinoma Contribute to Development of Resistance. Cells. 2022 Feb 11;11(4):634. (IF: 6.600; Cell Biology 53/195)
  24. YH Wu*, YP Hung, NC Chiu, RC Lee, CP Li, Y Chao, YM Shyr, SE Wang, SC Chen, SH Lin, YH Chen, YM Kang, SM Hsu, SH Yen, JY Wu, KD Lee, HE Tseng, JR Tsai, JH Tang, JF Chiou, T Burnouf, YJ Chen, PY Wang, LS Lu. Correlation between drug sensitivity profiles of circulating tumour cell-derived organoids and clinical treatment response in patients with pancreatic ductal adenocarcinoma. Eur J Cancer. 2022 Mar 17;166:208-218. (IF: 9.162; Oncology 33/242)
  25. CF Yeh*, YC Chin, W Hung, PI Huang, MY Lan. Vertebral artery stenosis predicts cerebrovascular diseases following radiotherapy for nasopharyngeal carcinoma. Support Care Cancer. 2022 Mar 31. (IF: 3.603; Health care Sciences & Services 34/107; Oncology 147/242; Rehabilitation 9/68)
  26. YQ Chen*, CY Hung, MT Wei, JC Kuo, MH Yang, HY Cheng, A Chiou. Snail Augments Nuclear Deformability to Promote Lymph Node Metastasis of Head and Neck Squamous Cell Carcinoma. Front Cell Dev Biol. 2022 Feb 21;10:809738. (IF: 6.684; Cell Biology 52/195; Developmental Biology 6/41)
  27. M Okada*, K Kato, BC Cho, M Takahashi,CY Lin, K Chin, S Kadowaki, MJ Ahn,Y  Hamamoto, Y Doki, CC Yen, Y Kubota, SB Kim, CH Hsu, E Holtved, I Xynos, Y Matsumura, A Takazawa, Y Kitagawa. Three-year follow-up and response-survival relationship of nivolumab in previously treated patients with advanced esophageal squamous cell carcinoma (ATTRACTION-3). Clin Cancer Res. 2022 Mar 16:clincanres.0985.2021. (IF: 12.531; Oncology 18/242)
  28. KL Lin*, TC Chao, MH Chen. Intravenous Immunoglobulin to Suppress Progression in a Patient With Advanced Breast Cancer. J Breast Cancer. 2022 Jun;25(3):253-258. (IF: 0.329(2009年); Oncology 156/166(2009年))
  29. SC Huang*, CC Lin, HW Teng, HH Lin, SC Chang, YT Lan, HS Wang, SH Yang, WS Chen, JK Jiang. A Long-Term and Large-Scale Real-World Study in Taiwan: Efficacy of Target Therapy in Stage IV Colorectal Cancer. Front Oncol. 2022 Mar 17;12:808808. (IF: 6.244; Oncology 62/242)
  30. WL Hwang*, TC Chen, HY Lin, MC Chang, PC Hsiao, LY Bai, CY Kuo, YC Chen, TC Liu, JP Gau, PN Wang, WS Hwang, MC Kuo, CY Liu, YC Liu, MC Ma, NW Su, CC Wang, YY Wu, M Yao, SP Yeh, HW Cheng, YM Lee, FC Ku, JL Tang. NOVEL-1st: an observational study to assess the safety and efficacy of nilotinib in newly diagnosed patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase in Taiwan. Int J Hematol. 2022 Feb 25. (IF: 2.490; Hematology 56/76)
  31. BC Cho*, HHF Loong, CM Tsai, MLP Teo, HR Kim, SM Lim, S Jain, S Olsen, K Park. Genomic Landscape of Non-Small Cell Lung Cancer (NSCLC) in East Asia Using Circulating Tumor DNA (ctDNA) in Clinical Practice. Curr Oncol. 2022 Mar 21;29(3):2154-2164. (IF: 3.677; Oncology 143/242)
  32. WC Wu*, TY Lin, MH Chen, YP Hung, CA Liu, RC Lee, YH Huang, Y Chao, SC Chen. Lenvatinib combined with nivolumab in advanced hepatocellular carcinoma-real-world experience. Invest New Drugs. 2022 Apr 28. (IF: 3.850; Oncology 138/242; Pharmacology & Pharmacy 138/242)
  33. IC Lee*, Y Chao, PC Lee, SC Chen, CT Chi, CJ Wu, KC Wu, MC Hou, YH Huang. Determinants of Survival and Post-Progression Outcomes by Sorafenib-Regorafenib Sequencing for Unresectable Hepatocellular Carcinoma. Cancers (Basel). 2022 Apr 15;14(8):2014. (IF: 6.639; Oncology 51/242)
  34. CY Liao*, CY Lee, CY Wei, Y Chao, YH Huang, MC Hou, YH Su, JC Wu, CW Su. Differential prognoses among male and female patients with hepatocellular carcinoma. J Chin Med Assoc. 2022 May 1;85(5):554-565. (IF: 2.743; Medicine, General & Internal 62/167)
  35. YW Chen*, YY Lee, CF Lin, TY Huang, SH Ke, PF Mu, PS Pan, JK Chen, TL Lan, PC Hsu, ML Liang, HH Chen, FC Chang, CC Wu, SC Lin, JC Lee, SK Chen, HM Liu, JJ Peir, HY Tsai, KH Lin, NJ Peng, KH Chen, YH Wu, YM Kang, WC Yang, SC Liou, WH Huang, H Tanaka, TT Wong, Y Chao, FI Chou. Compassionate Treatment of Brainstem Tumors with Boron Neutron Capture Therapy: A Case Series. Life (Basel). 2022 Apr 10;12(4):566. (IF: 3.817; Biology 27/93)
  36. YJ Chen*, CW Su, CY Wei, GY Chau , PH Chen, Y Chao, YH Huang, JC Wu, TC Yang, PC Lee, MC Hou. Comparison of prognoses between cirrhotic and non-cirrhotic patients with hepatocellular carcinoma and esophageal varices undergo surgical resection. J Chin Med Assoc. 2022 May 4. (IF: 2.743; Medicine, General & Internal 62/167)
  37. YP Yang*, WY Lai, TW Lin, YY Lin, Y Chien, YC Tsai, HY Tai, CL Wang, YY Liu, PI Huang, YW Chen, WL Lo, CY Wang. Autophagy Reprogramming Stem Cell Pluripotency and Multiple-lineage Differentiation. J Chin Med Assoc. 2022 Apr 5. (IF: 2.743; Medicine, General & Internal 62/167)
  38. SB Qiu*, PY Liu, BC Wang, PR Chen, JH Xiao, TY Hsu, KL Pan, ZY Lai, YW Chen, YC Chen, JK Chen, PS Pan. Protection-Free Strategy for the Synthesis of Boro-Depsipeptides in Aqueous Media under Microwave-Assisted Conditions. Molecules. 2022 Apr 4;27(7):2325. (IF: 4.412; Biochemistry & Molecular Biology 115/295; Chemistry, Multidisciplinary 63/178; Chemistry, Organic n/a)
  39. CL Lai*, TH Chen, PM Chang, SK Tai, PY Chu, MH Yang. Efficacy of cetuximab-containing regimens in the treatment of recurrent/metastatic head and neck cancer after progression to immune checkpoint inhibitors. J Chin Med Assoc. 2022 May 2. (IF: 2.743; Medicine, General & Internal 62/167)
  40. AN Tsao*, YS Chuang, YC Lin, Y Su, TC Chao. Dinaciclib inhibits the stemness of two subtypes of human breast cancer cells by targeting the FoxM1 and Hedgehog signaling pathway. Oncol Rep. 2022 May;47(5):105. (IF: 3.906; Oncology 134/242)
  41. CP Huang*, YF Tsai, YS Lin, CY Liu, TT Huang, CC Huang, JH Chiu, LM Tseng. Overexpression of multiple epidermal growth factor like domains 11 rescues anoikis survival through tumor cells-platelet interaction in triple negative breast Cancer cells. Life Sci. 2022 Jun 15;299:120541. (IF: 5.037; Medicine, Research & Experimental 46/140; Pharmacology & Pharmacy 65/276; Biology n/a)
  42. YC Chang*, CH Li, MH Chan, MH Chen, CN Yeh, M Hsiao. Regorafenib inhibits epithelial-mesenchymal transition and suppresses cholangiocarcinoma metastasis via YAP1-AREG axis. Cell Death Dis. 2022 Apr 21;13(4):391. (IF: 8.469; Cell Biology 37/195)
  43. TH Wei*, Ye BW, PS Wu, CP Li, Y Chao, PC Lee, YH Huang, KC Lee, MC Hou. Outcomes of patients with malignant duodenal obstruction after receiving self-expandable metallic stents: A single center experience. PLoS One. 2022 May 25;17(5):e0268920. (IF: 3.240; Multidisciplinary Sciences 26/72; Biology n/a)
  44. CY Lee*, GY Chau, CY Wei, Y Chao, YH Huang, Tl Huo, MC Hou, YH Su, JC Wu, CW Su. Surgical resection could provide better outcomes for patients with hepatocellular carcinoma and tumor rupture. Sci Rep. 2022 May 18;12(1):8343. (IF: 4.380; Multidisciplinary Sciences 36/242)
  45. KW Huang*, PC Lee, Y Chao, CW Su, IC Lee, KH Lan, CJ Chu, YP Hung, SC Chen, MC Hou, YH Huang. Durable objective response to sorafenib and role of sequential treatment in unresectable hepatocellular carcinoma. Ther Adv Med Oncol. 2022 May 22;14:17588359221099401. (IF: 8.168; Oncology 36/242)
  46. PW Huang*, SJ Peng, DH Pan, HC Yang, JT Tsai, CY Shiau, IC Su, CJ Chen, HM Wu, CJ Lin, WY Chung, WY Guo, WL Lo, SW Lai, CC Lee. Compactness index: a radiosurgery outcome predictor for patients with unruptured brain arteriovenous malformations. J Neurosurg. 2022 May 20:1-10. (IF: 5.115; Clinical Neurology 46/208; Surgery 22/211; Neurosciences n/a)
  47. WT Ho*, JS Chang, TC Chen, JK Wang, SW Chang, MH Yang, TS Jou, IJ Wang. Inhibition of Rho-associated protein kinase activity enhances oxidative phosphorylation to support corneal endothelial cell migration. FASEB J. 2022 Jul;36(7):e22397. (IF: 5.192; Biochemistry & Molecular 16/34; Biology 14/93; Cell Biology 77/195)
  48. JM Lee*, MH Chen, KY Chou, Y Chao, MH Chen, CY Tsai. Novel immunoprofiling method for diagnosing SLE and evaluating therapeutic response. Lupus Sci Med. 2022 Jun;9(1):e000693. (IF: 4.687; Rheumatology 16/34)
  49. RL Sun*, SW Pan, JY Feng, CY Liu, YM Chen. Osteoblastic flare phenomenon in a patient treated for disseminated non-tuberculous mycobacterial infection. Thorax. 2022 Jun 23:thoraxjnl-2021-218351. (IF: 9.106; Respiratory System 9/65)
  50. CJ Huang*, WY Huang, CY Chen, YJ Chao, NJ Chiang, YS Shan. Cancer-cell-derived cell-free DNA can predict distant metastasis earlier in pancreatic cancer: a prospective cohort study. Ther Adv Med Oncol. 2022 Jun 16;14:17588359221106558. (IF: 5.485; Oncology 80/245)
  51. YY Su*, YL Ting, CJ Wang, YJ Chao, TK Liao, PJ Su, NJ Chiang, IC Liao, YT Yu, YS Liu, HM Tsai, YJ Li, CJ Huang, IT Liu, HJ Tsai, CJ Yen, YS Shan, LT Chen. Improved survival with induction chemotherapy and conversion surgery in locally advanced unresectable pancreatic cancer: a single institution experience. Am J Cancer Res. 2022 May 15;12(5):2189-2202. (IF: 5.942; Oncology 71/245)
  52. NJ Chiang*, YC Hou, KT Tan, HW Tsai, YJ Lin, YC Yeh, LT Chen, YF Hou, MH Chen, YS Shan. The immune microenvironment features and response to immunotherapy in EBV-associated lymphoepithelioma-like cholangiocarcinoma. Hepatol Int. 2022 Jul 3. (IF: 9.052; Gastroenterology & Hepatology 16/93)
  53. SH Yang, NJ Chiang *, SC Chiu, WC Chou, LY Bai, CP Li, YY Su, TJ Chiu, SC Chuang, CM Peng, DC Chan, JS Chen, CJ Yen, YY Chen, CF Chiu, LT Chen, YS Shan. The impact of spleen volume on the survival of metastatic pancreatic adenocarcinoma patients receiving nanoliposomal irinotecan. Am J Cancer Res. 2022 Apr 15;12(4):1884-1898. (IF: 5.942; Oncology 71/245)
  54. CY Tang*, JF Hang, YP Hung, NC Chiu, JI Lai, MH Chen, CY Liu, MH Yang, Y Chao, PM Chang. A generational comparison for unfavorable cancer of unknown primary in a single institute over 20 years. Cancer Med. 2022 Jul 3. (IF: 4.711; Oncology 106/245)
  55. YM Kang*, H Ishikawa, T Inaniwa, Y Iwai, N Matsufuji, G Kasuya, N Okonogi, YM Liu, Y Chao, M Wakatsuki, H Tsujii, H Tsuji. The clinical relative biological effectiveness and prostate-specific antigen kinetics of carbon-ion radiotherapy in low-risk prostate cancer. Cancer Med. 2022 Jul 19. (IF: 4.711; Oncology 106/245)
  56. Z Lu*, S Yang, X Luo, Y Shi, JS Lee, S Deva, T Liu, Y Chao, Y Zhang, R Huang, Y Xu, Z Shen, L Shen. The combination of gene hyperamplification and PD-L1 expression as a biomarker for the clinical benefit of tislelizumab in gastric/gastroesophageal junction adenocarcinoma. Gastric Cancer. 2022 Jul 2. (IF: 7.708; Gastroenterology & Hepatology 21/93; Oncology 49/245)
  57. NJ Chiang*, KT Tan, LY Bai, CF Hsiao, CY Huang, YP Hung, CJ Huang, SC Chen, YS Shan, Y Chao, YH Huang, IC Lee, PC Lee, YY Su, SJ Chen, CN Yeh, LT Chen, MH Chen. Impaired Chromatin Remodeling Predicts Survival to Modified Gemcitabine and S-1 plus Nivolumab in Advanced Biliary Tract Cancer: A Phase II T1219 Study. Clin Cancer Res. 2022 Jul 18:CCR-22-1152. (IF: 13.801; Oncology 17/245)
  58. IC Lai*, CH Liao, MH Hu, CL Chang, GM Lai, TJ Chiou, S Hsia, WL Tsai, YY Lin, SE Chuang, J Whang-Peng, HY Chen, CJ Yao. Selenium Yeast and Fish Oil Combination Diminishes Cancer Stem Cell Traits and Reverses Cisplatin Resistance in A549 Sphere Cells. Nutrients. 2022 Aug 7;14(15):3232. (IF: 6.706; Nutrition & Dietetics 15/90)
  59. HW Ko*, CT Chiu, CL Wang, TY Yang, CY Liu, CT Yu, LC Tseng, CS Kuo, CC Wang, MH Yang, CT Yang. Overall Survival Improvement in Patients with Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer and Bone Metastasis Treated with Denosumab. Cancers (Basel). 2022 Jul 17;14(14):3470. (IF: 6.575; Oncology 60/245)
  60. LC Lin*, WK Huang, CC Yen, CY Yang, MT Sung, SMN Wong, DTT Chua, SWM Lee, JS Chen, CN Yeh. Compassionate Use of Ripretinib for Patients With Metastatic Gastrointestinal Stromal Tumors: Taiwan and Hong Kong Experience. Front Oncol. 2022 Jun 29;12:883399. (IF: 5.738; Oncology 78/245)
  61. CY Lin*, CJ Yu, CY Liu, TC Chao, CC Huang, LM Tseng, JI Lai. CDK4/6 inhibitors downregulate the ubiquitin-conjugating enzymes UBE2C/S/T involved in the ubiquitin-proteasome pathway in ER + breast cancer. Clin Transl Oncol. 2022 Aug 2. (IF: 3.340; Oncology 165/245)
  62. JL Chen*, PY Chu, CT Huang, TT Huang, WL Wang, YH Lee, YY Chang, MS Dai, CW Shiau, CY Liu. Interfering B cell receptor signaling via SHP-1/p-Lyn axis shows therapeutic potential in diffuse large B-cell lymphoma. Mol Med. 2022 Aug 8;28(1):93. (IF: 6.400; Biochemistry & Molecular biology 66/296; Cell Biology 64/194; Medicine, Research & Experimental 38/139)
  63. LJ Li*, CH Li, PM Chang, TC Lai, CY Yong, SW Feng, M Hsiao, WM Chang, CF Huang. Dehydroepiandrosterone (DHEA) Sensitizes Irinotecan to Suppress Head and Neck Cancer Stem-Like Cells by Downregulation of WNT Signaling. Front Oncol. 2022 Jul 13;12:775541. (IF: 5.738; Oncology 78/245)
  64. YC Hou*, CY Chen, CJ Huang, CJ Wang, YJ Chao, NJ Chiang, HC Wang, HL Tung, HC Liu, YS Shan. The Differential Clinical Impacts of Cachexia and Sarcopenia on the Prognosis of Advanced Pancreatic Cancer. Cancers (Basel). 2022 Jun 26;14(13):3137. (IF: 6.575; Oncology 60/245)
  65. YY Su, NJ Chiang *, CP Li, CJ Yen, SH Yang, WC Chou, JS Chen, TJ Chiu, YY Chen, SC Chuang, LY Bai, CF Chiu, CM Peng, DC Chan, SC Chiu, YH Yang, YS Shan, LT Chen. Dosing Pattern and Early Cumulative Dose of Liposomal Irinotecan in Metastatic Pancreatic Cancer: A Real-World Multicenter Study. Front Oncol. 2022 Jun 22;12:800842. (IF: 5.738; Oncology 78/245)
  66. LY Bai*, CP Li, YS Shan, SC Chuang, JS Chen, NJ Chiang, YY Chen, HH Tsou, MH Chuang, CF Chiu, TW Liu, LT Chen. A prospective phase II study of biweekly S-1, leucovorin, and gemcitabine in elderly patients with locally advanced or metastatic pancreatic adenocarcinoma - The Taiwan Cooperative Oncology Group T1217 study. Eur J Cancer. 2022 Aug 3;173:123-132. (IF: 10.002; Oncology 31/245)
  67. M Simonelli*, E Garralda, F Eskens, M Gil-Martin, CJ Yen, R Obermannova, Y Chao, S Lonardi, B Melichar, V Moreno, ML Yu, A Bongiovanni, E Calvo, S Rottey, JP Machiels, A Gonzalez-Martin, L Paz-Ares, CL Chang, W Mason, CC Lin, DA Reardon, M Vieito, A Santoro, R Meng, G Abbadessa, F Menas, H Lee, Q Liu, C Combeau, N Ternes, S Ziti-Ljajic, C Massard. Isatuximab plus atezolizumab in patients with advanced solid tumors: results from a phase I/II, open-label, multicenter study. ESMO Open. 2022 Aug 17;7(5):100562. (IF: 6.883; Oncology 57/245)
  68. HR Liao*, CL Chiang, CI Shen, CJ Chen, HC Yang, HM Wu, YH Luo, YS Hu, CJ Lin, WY Chung, CY Shiau, WY Guo, DH Pan, CC Lee. EGFR mutant status and tyrosine-kinase inhibitors affect the GKRS outcomes for NSCLC brain metastases.J Neurooncol. 2022 Aug 17. (IF: 4.506; Clinical Neurology 73/212; Oncology 112/245)
  69. KT Hong*, JW Han, H Fuji, HK Byun, KN Koh, RX Wong, HL Lee, HI Yoon, JH Lee, JH Phi, SK Kim, DS Kim, CJ Lyu, JY Choi, HJ Kang, YW Chen, YY Lee, HJ Im, YS Ra, Ahn S Do, SYY Low, WS Looi, HJ Park, YG Suh, CO Suh, KC Wang, EEK Tan, TT Wong, JY Kim. Outcomes of intracranial non-germinomatous germ cell tumors: a retrospective Asian multinational study on treatment strategies and prognostic factors. J Neurooncol. 2022 Aug 31. (IF: 4.506; Clinical Neurology 73/212; Oncology 112/245)
  70. HY Cheng*, CH Hsieh, PH Lin, YT Chen, DS Hsu, SK Tai, PY Chu, MH Yang. Snail-regulated exosomal microRNA-21 suppresses NLRP3 inflammasome activity to enhance cisplatin resistance. J Immunother Cancer. 2022 Aug;10(8):e004832. (IF: 12.487; Immunology 18/161; Oncology 25/245)
  71. CC Huang*, YF Tsai, CY Liu, PJ Lien, YS Lin, TC Chao, CJ Feng, YJ Chen, JI Lai, NN Phan, CY Hsu, JH Chiu, LM Tseng. ASO Visual Abstract: Prevalence of Tumor Genomic Alterations in Homologous Recombination Repair Genes Among Taiwanese Breast Cancers. Ann Surg Oncol. 2022 Aug 30. (IF: 4.339; Oncology 117/245; Surgery 37/211)
  72. WC Lin*, CC Lin, YY Lin, WH Yang, YC Twu, HW Teng, WL Hwang. Molecular actions of exosomes and their theragnostics in colorectal cancer: current findings and limitations. Cell Oncol (Dordr). 2022 Sep 1. (IF: 7.051; Cell Biology 58/194; Oncology 37/245; Pathology 9/77)
  73. CT Chen*, YH Feng, CJ Yen, SC Chen, YT Lin, LC Lu, CH Hsu, AL Cheng, YY Shao. Prognosis and treatment pattern of advanced hepatocellular carcinoma after failure of first-line atezolizumab and bevacizumab treatment. Hepatol Int. 2022 Aug 20. (IF: 9.052; Gastroenterology & Hepatology 16/93)
  74. CC Hsieh*, SH Hsu, CY Lin, HJ Liaw, TW Li, KY Jiang, NJ Chiang, SH Chen, BW Lin, PC Chen, RH Chan, PC Lin, YM Yeh, CH Shen. CHK2 activation contributes to the development of oxaliplatin resistance in colorectal cancer. Br J Cancer. 2022 Aug 23. (IF: 9.089; Oncology 37/245)
  75. YY Shao*, YH Feng, CJ Yen, TS Yang, YC Shen, Y Chao, JS Chen, CY Su, WJ Chen, HL Hsiang, CH Hsu. Bevacizumab and atezolizumab as first-line therapy for advanced hepatocellular carcinoma: A Taiwanese subgroup analysis on efficacy and safety. J Formos Med Assoc. 2022 Sep 21:S0929-6646(22)00355-2. (IF: 3.871; Medicine, General & Internal 61/172)
  76. WJ Lee*, KH Lin, JS Wang, WH Sheu, CC Shen, CN Yang, SM Wu, LW Shen, SH Lee, DW Lai, KL Lan, CW Tung, SH Liu, ML Sheu. Aryl hydrocarbon receptor deficiency augments dysregulated microangiogenesis and diabetic retinopathy. Biomed Pharmacother. 2022 Sep 21;155:113725. (IF: 7.419; Medicine, Research & Experimental 30/139; PHARMACOLOGY & PHARMACY 26/279)
  77. LW Wang*, YS Liu, JK Jiang. The effect of Mitomycin-C in neoadjuvant concurrent chemoradiotherapy for rectal cancer. J Chin Med Assoc. 2022 Oct 4. (IF: 3.396; Medicine, General & Internal 71/172)
  78. YC Lin*, YJ Lee, YW Chen, SY Wang, FI Chou. Evaluation of the Key Advantages between Two Modalities of Boronophenylalanine Administration for Clinical Boron Neutron Capture Therapy Using an Animal Model. Cells. 2022 Sep 1;11(17):2736. (IF: 7.666; Cell Biology 51/194)
  79. PH Hsu*, YH Chen, PI Huang, PA Hwang. Skin proteomic profiling of irradiation-induced fibrosis and its modulation by low molecular weight fucoidan via tight junction pathway. Biomed Pharmacother. 2022 Sep;153:113417. (IF: 7.419; Medicine, Research & Experimental 30/139; PHARMACOLOGY & PHARMACY 26/279)
  80. JY Chen*, HH Chou, SC Lim, YJ Huang, KC Lai, CL Guo, CY Tung, CT Su, J Wang, E Liu, HF Han, PY Yeh, CM Hu, AR Dunn, CW Frank, YC Wu, MH Yang, YC Chang. Multiomic characterization and drug testing establish circulating tumor cells as an ex vivo tool for personalized medicine. iScience. 2022 Sep 6;25(10):105081. (IF: 6.107; Multidisciplinary Sciences 15/73)
  81. TW Chen*, CL Hsu, RL Hong, JC Lee, K Chang, CW Yu, SC Chen, JC Guo, ML Chen, MC Hsu, TF Kung, AL Cheng, CC Yen. A Single-Arm Phase Ib/II Study of Lenvatinib Plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma. Clin Cancer Res. 2022 Sep 21:CCR-22-2092. (IF: 13.801; Oncology 17/245)
  82. CY Lin*, CJ Yu, CI Shen,CY Liu, TC Chao, CC Huang, LM Tseng, JI Lai. IKZF3 amplification frequently occurs in HER2-positive breast cancer and is a potential therapeutic target. Med Oncol. 2022 Sep 30;39(12):242. (IF: 3.738; Oncology 144/245)
  83. CY Lin*, CJ Yu, CY Liu, TC Chao, CC Huang, LM Tseng, JI Lai. Correction to: CDK4/6 inhibitors downregulate the ubiquitin-conjugating enzymes UBE2C/S/T involved in the ubiquitin-proteasome pathway in ER + breast cancer. Clin Transl Oncol. 2022 Nov;24(11):2251-2253. (IF: 3.340; Oncology 165/245)
  84. YH Lai*, KC Tung, SC Chen. Durable response to olaparib combined low-dose cisplatin in advanced hepatocellular carcinoma with FANCA mutation: A case report. Medicine (Baltimore). 2022 Sep 30;101(39):e30719. (IF: 1.817; Medicine, General & Internal 122/172)
  85. KC Lai*, YH Hsiao, SC Chen. Pulse corticosteroid therapy in the treatment of steroid-refractory immune checkpoint inhibitor-related pneumonitis: Case report and review. Front Immunol. 2022 Aug 31;13:994064. (IF: 8.786; Immunology 33/161)
  86. IC Lee*, KH Lan, CW Su, CP Li, Y Chao, HC Lin, MC Hou, YH Huang. Efficacy and Renal Safety of Prophylactic Tenofovir Alafenamide for HBV-Infected Cancer Patients Undergoing Chemotherapy. Int J Mol Sci. 2022 Sep 26;23(19):11335. (IF:5.738; Biochemistry & Molecular Biology 69/297; 50/179 Chemistry, Multidisciplinary)
  87. LC Lin*, WK Huang, CC Yen, CY Yang, MT Sung, NSM Wong, DTT Chua, SWM Lee, JS Chen, CN Yeh. Corrigendum: Compassionate use of ripretinib for patients with metastatic gastrointestinal stromal tumors: Taiwan and Hong Kong experience. Front Oncol. 2022 Oct 13;12:1028118. (IF: 5.738; Oncology 78/245)
  88. JI Lai*, TC Chao, CY Liu, CC Huang, LM Tseng. A systemic review of taxanes and their side effects in metastatic breast cancer. Front Oncol. 2022 Oct 11;12:940239. (IF: 5.738; Oncology 78/245)
  89. HL Ho*, FY Wang, CL Chiang, CM Tsai, CH Chiu, TY Chou. Dynamic Assessment of Tissue and Plasma EGFR-Activating and T790M Mutations with Droplet Digital PCR Assays for Monitoring Response and Resistance in Non-Small Cell Lung Cancers Treated with EGFR-TKIs. Int J Mol Sci. 2022 Sep 26;23(19):11353. (IF: 6.208; Chemistry, Multidisciplinary 50/179)
  90. JM Lee*, YP Hung, KY Chou, CY Lee, SR Lin, YH Tsai, WY Lai, YY Shao, C Hsu, CH Hsu, Y Chao. Artificial intelligence-based immunoprofiling serves as a potentially predictive biomarker of nivolumab treatment for advanced hepatocellular carcinoma. Front Med (Lausanne). 2022 Nov 8;9:1008855. (IF: 5.058; Medicine, General & Internal 71/172)
  91. MC Chen*, HY Su, YH Su, KH Huang, WL Fang, CW Lin, MH Chen, Y Chao, SS Lo, AF Li, CW Wu. The clinicopathological and genetic differences among gastric cancer patients with no recurrence, early recurrence and late recurrence after curative surgery. J Chin Med Assoc. 2022 Nov 15. (IF: 3.396; Medicine, General & Internal 71/172)
  92. IC Lee *, PC Lee, Y Chao, CT Chi, CJ Wu, YP Hung, CW Su, MC Hou, YH Huang. Application and Impact of Antiviral Therapy for Patients with HBV-Related Hepatocellular Carcinoma Receiving Sorafenib and Lenvatinib Treatment. Viruses. 2022 Oct 26;14(11):2355. (IF: 5.818; VIROLOGY 14/37)
  93. CC Fu*, CY Wei, CJ Chu, PC Lee, TI Huo, YH Huang, Y Chao, MC Hou, JC Wu, CW Su. The outcomes and prognostic factors of patients with hepatocellular carcinoma and normal serum alpha fetoprotein levels. J Formos Med Assoc. 2022 Nov 28:S0929-6646(22)00428-4. (IF: 3.871; MEDICINE, GENERAL & INTERNAL 61/172)
  94. PW Shueng*, CC Huang, YM Liu, YH Wu, PI Huang, SH Yen, KH Lin, CX Hsu. Combined modality therapy for patients with esophageal squamous cell carcinoma: Radiation dose and survival analyses. Thorac Cancer. 2022 Nov 9. (IF: 3.223; ONCOLOGY  171/245; RESPIRATORY SYSTEM 40/66)
  95. TL Lee*, TH Chen, YJ Kuo, HY Lan, MH Yang, PY Chu. Tumor-associated tissue eosinophilia promotes angiogenesis and metastasis in head and neck squamous cell carcinoma. Neoplasia. 2022 Nov 18;35:100855. (IF: 6.218; Oncology 66/245)
  96. YH Chen*, JY Hsu, CT Chu, YW Chang, JR Fan, MH Yang, HC Chen. Loss of cell-cell adhesion triggers cell migration through Rac1-dependent ROS generation. Life Sci Alliance. 2022 Nov 29;6(2):e202201529. (IF: 5.781; Biology 17/94)
  97. KM Rau*, SC Shun, SH Hung, HL Chou, CL Ho, TC Chao, CY Liu, CT Lien, MY Hong, CJ Wu, LY Tsai, SW Jane, RK Hsieh. Management of cancer-related fatigue in Taiwan: an evidence-based consensus for screening, assessment and treatment. Jpn J Clin Oncol. 2022 Nov 9:hyac164. (IF: 2.925; Oncology 183/245)
  98. YR Pan*, CE Wu, WK Huang, MH Chen, KH Lan, CN Yeh.  Chimeric immune checkpoint protein vaccines inhibit the tumorigenesis and growth of rat cholangiocarcinoma. Front Immunol. 2022 Oct 20;13:982196. (IF: 8.787; Immunology 35/162)
  99. SY Chung*, YC Chang, DS Hsu, YC Hung, ML Lu, YP Hung, NJ Chiang, CN Yeh, M Hsiao, J Soong, Y Su, MH Chen. A G-quadruplex stabilizer, CX-5461 combined with two immune checkpoint inhibitors enhances in vivo therapeutic efficacy by increasing PD-L1 expression in colorectal cancer. Neoplasia. 2022 Nov 25;35:100856. (IF: 6.218; Oncology 66/245)
  100. Y Wang*, CH Tsai, TS Chu, YT Hung, MY Lee, HH Chen, LT Chen, r TR Ge, YH Wang, NJ Chiang, LD Liao. Revisiting the cerebral hemodynamics of awake, freely moving rats with repeated ketamine self-administration using a miniature photoacoustic imaging system. Neurophotonics. 2022 Oct;9(4):045003. (IF: 4.212; Neurosciences 121/275; Optics 25/101)

最後更新：

回到最上